Artelo Biosciences (ARTL) Return on Capital Employed (2015 - 2025)
Artelo Biosciences (ARTL) posted quarterly Return on Capital Employed of 2236.08% for Q4 2025, up 247994.0% year-over-year from N/an in Q4 2024, and down 1.42% quarter-over-quarter from 2268.25% in Q3 2025.
Artelo Biosciences (ARTL) Return on Capital Employed (2015 - 2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported Return on Capital Employed for 11 consecutive years, with 2236.08% the latest figure, recorded in Q4 2025.
- In Q4 2025, Return on Capital Employed rose 247994.0% year-over-year to 2236.08%; the TTM figure through Dec 2025 stood at 2236.08% (up 247994.0% YoY), while the FY2025 annual figure was 3872.33%, up 401472.0% from the prior year.
- Return on Capital Employed eased to 2236.08% in Q4 2025 per ARTL's latest filing, from 2268.25% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 2268.25% in Q3 2025 and bottomed at 759.92% in Q1 2025.
- Historically, Return on Capital Employed has averaged 153.47% across 5 years, with a median of 54.63% in 2021.
- On a YoY basis, Return on Capital Employed climbed as much as 247994 bps in 2025 and fell as far as 66676 bps in 2025.
- Artelo Biosciences' Return on Capital Employed stood at 51.85% in 2021, then rose by 3 bps to 50.37% in 2022, then slumped by 52 bps to 76.5% in 2023, then sank by 219 bps to 243.86% in 2024, then surged by 1017 bps to 2236.08% in 2025.
- Business Quant data shows ARTL's Return on Capital Employed at 2236.08% in Q4 2025, 2268.25% in Q3 2025, and 593.24% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Artelo Biosciences | 107,735.40 | -492,264.60 | - | 2,236.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2,236.08% |
| Sep 30, 2025 | 2,268.25% |
| Jun 30, 2025 | 593.24% |
| Mar 31, 2025 | -759.92% |
| Dec 31, 2024 | -243.86% |
| Sep 30, 2024 | -135.57% |
| Jun 30, 2024 | -130.42% |
| Mar 31, 2024 | -93.16% |
| Dec 31, 2023 | -76.50% |
| Sep 30, 2023 | -66.59% |
| Jun 30, 2023 | -58.25% |
| Mar 31, 2023 | -57.09% |
| Dec 31, 2022 | -50.37% |
| Sep 30, 2022 | -40.83% |
| Jun 30, 2022 | -42.96% |
| Mar 31, 2022 | -39.04% |
| Nov 30, 2021 | -51.85% |
| Aug 31, 2021 | -78.06% |
| May 31, 2021 | -52.18% |
| Feb 28, 2021 | -51.59% |